Desonumab Discontinuation for Osteoporosis: What Are the Risks? – Rheumatology Advisor (registration)

Rheumatology Advisor (registration)Desonumab Discontinuation for Osteoporosis: What Are the Risks?Rheumatology Advisor (registration)Discontinuing desonumab therapy in osteoporosis may increase the risk of vertebral fractures, according to a systematic literature review recently published in Bone.1 In addition, measures and treatments aimed at curbing treatment-associated bone loss …

Source:: Osteoporosis Feed

      

Last modified: August 31, 2017